论文部分内容阅读
目的:观察长春瑞滨联合顺铂方案治疗ER、PR、HER-2均阴性蒽环类耐药的晚期转移性乳腺癌的疗效和安全性。方法:36例对蒽环类或紫杉类耐药晚期转移性乳腺癌患者,术后病理经免疫组化证实ER、PR、HER-2均阴性,给予长春瑞滨25mg/m2静推,第1、8天;顺铂:25mg/m2静脉滴注,第1～3天。21天为1周期,至少2个周期,2周期后评价疗效和毒副反应。结果:36例患者均可评价疗效,获完全缓解(CR)2例(5.6%);部分缓解(PR)13例(36.1%);稳定(SD)15例(41.7%);进展(PD)6例(16.7%);总有效率(CR+PR)为41.7%;中位疾病进展时间为5个月。主要不良反应包括骨髓抑制、静脉炎和胃肠道反应,无化疗相关死亡。结论:长春瑞滨联合顺铂方案对蒽环类或紫杉类耐药的转移性三阴性乳腺癌有较好的近期疗效,不良反应可耐受,可作为临床推广的解救方案之一。
OBJECTIVE: To observe the efficacy and safety of vinorelbine plus cisplatin in the treatment of advanced metastatic breast cancer with both anthracycline-resistant and anthracycline-resistant ER, PR and HER-2. Methods: Thirty-six patients with anthracycline or taxane-resistant advanced metastatic breast cancer were enrolled in this study. Postoperative pathology was confirmed by immunohistochemistry to be negative for ER, PR and HER-2. 1,8 days; cisplatin: 25mg / m2 intravenous drip, the 1st to 3 days. 21 days for a period of at least 2 cycles, 2 cycles after the evaluation of efficacy and toxicity. Results: Thirty-six patients were evaluated for complete response (CR) in 2 patients (5.6%), partial response (PR) in 13 patients (36.1%), stable (SD) in 15 patients 6 cases (16.7%); total effective rate (CR + PR) was 41.7%; median disease progression time was 5 months. The main adverse reactions include myelosuppression, phlebitis and gastrointestinal reactions, and no chemotherapy-related death. CONCLUSION: The combination of vinorelbine and cisplatin has good short-term curative effect on anthracycline-resistant or taxane-resistant metastatic triple negative breast cancer. The regimens are tolerable and can be used as one of the solutions for clinical promotion.